

Bacterial Peptidoglycans from Microbiota in Neurodevelopment and Behavior

Ayoze Gonzalez-Santana, Rochellys Diaz Heijtz

▶ To cite this version:

Ayoze Gonzalez-Santana, Rochellys Diaz Heijtz. Bacterial Peptidoglycans from Microbiota in Neurodevelopment and Behavior. Trends in Molecular Medicine, 2020, 26, pp.729 - 743. 10.1016/j.molmed.2020.05.003 . hal-03492013

HAL Id: hal-03492013 https://hal.science/hal-03492013

Submitted on 22 Aug 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Manuscript_60b9e6a3d22bb0c4877cebe94c0cd1bd Trends in Molecular Medicine

1		
2		
3	Bacterial Peptidoglycans from Microbiota in Neurodevelopment and Behavior	
4		
5	Ayoze Gonzalez Santana ¹ and Rochellys Diaz Heijtz ^{1,2*}	
6	¹ Department of Neuroscience, Karolinska Institutet, Biomedicum, 171 77 Stockholm,	
7	Sweden	
8	² Inserm U1239, University of Rouen Normandy, 76000 Rouen, France	
9		
10		
11		
12		
13		
14		
15		
16		
17		
18	* Correspondence: rochellys.heijtz@ki.se (R. Diaz Heijtz)	
19		
20		
21		
22		
23	Key words: Microbiome; Peptidoglycan recognition proteins, NOD-like receptors, Placenta,	
24	Anxiety-like behavior, HPA-axis, cognition, Pregnancy.	
25		

2	\sim
2	ь

27 Abstract

It is becoming increasingly recognized that the gut microbiota profoundly influences many 28 aspects of host development and physiology, including the modulation of brain development 29 and behavior. However, the precise molecular mechanisms and signaling pathways involved 30 in the communication between the microbiota and the developing brain remain to be fully 31 elucidated. Germline-encoded pattern recognition receptors that recognize conserved 32 33 microbial molecular signatures, such as bacterial surface molecules (e.g., peptidoglycans) have emerged as potential key regulators of gut microbiota-brain interactions. In this review, 34 we highlight current evidence supporting multiple and essential roles for peptidoglycans and 35 their sensing molecules well beyond innate immunity, extending to neurodevelopment and 36 behavior. In addition, the possible implications of the peptidoglycan signaling pathway for 37 the pathogenesis of neurodevelopmental disorders such as autism spectrum disorder is 38 considered. 39

Trends in Molecular Medicine

40 The Gut Microbiota: A Key Regulator of Neurodevelopment and Behavior

The mammalian gastrointestinal tract harbors a dynamic and complex community of 41 microorganisms, including bacteria, archaea, fungi, and viruses-known collectively as the gut 42 microbiota. Microbial colonization is an evolution-driven process that has provided mutual 43 benefits to both microbes and the mammalian host. The first major exposure to a complex 44 microbiota occurs during birth via vertical mother-to-infant microbial transmission (i.e., 45 when infants are exposed to their maternal vaginal, fecal and perineal microbes), and is a 46 pivotal event early in life determining the initial assembly of the infant gut microbiota [1] 47 48 (Box 1). The bacterial population is currently the most well characterized. Although the ratio between bacteria to human cells is close to one [2], the total number of bacterial genes in 49 the collective human microbiome is estimated to be 2-20 million, exceeding the human 50 genome by at least a factor of 100 [3, 4]. Many of these bacterial genes encode enzymes 51 that can perform metabolic functions not achievable by the host and produce metabolites 52 that can impact host health and disease. Over the past decades, studies have demonstrated 53 that gut bacteria interact and perform numerous critical functions for their host, including 54 55 dietary energy extraction, the production of vitamins, protection against invading gut pathogens [5, 6], as well as promoting the development and function of the immune system 56 57 [1, 7]. Recent investigations have revealed that the gut microbiota exerts a broader range of effects on host physiology and development beyond the gastrointestinal tract, including the 58 modulation of brain development and behavior [8, 9]. 59

60

61 In a landmark study, Sudo and colleagues in 2004 showed that postnatal bacterial 62 colonization affects the early life programming of the hypothalamic–pituitary–adrenal (HPA) axis, the central stress response system [10]. More specifically, they took advantage of germ-63 64 free (GF; devoid of bacteria throughout life) mice to assess how the absence of microbiota affects the HPA-axis response to various stress modalities. In adult GF mice, exposure to a 65 mild restraint stress induced an exaggerated release of adrenocorticotropic hormone (ACTH) 66 and corticosterone compared with control mice with a normal composition of microbiota 67 68 and no specific pathogens (known as specific-pathogen-free mice; SPF). The exaggerated HPA stress responses of GF mice were fully reversed through colonization with 69 Bifidobacterium infantis. Several years later, Diaz Heijtz and colleagues demonstrated that 70 the absence of microbiota profoundly affects motor activity and anxiety-like behavior, the 71

72 expression of four canonical pathways (i.e., Krebs cycle, synaptic long-term potentiation, 73 steroid hormone metabolism and cAMP-mediated signaling) and the turnover of neurotransmitters, including dopamine and serotonin [11]. Importantly, microbiota 74 75 reconstitution of GF mice in early life partially normalized their behavioral phenotypes, whereas colonization of adult GF mice had no effect. Together, these observations led to the 76 77 concept of a sensitive period early in life, in which microbial colonization of the gut can influence brain development, function and behavior. Around the same time other groups 78 independently published similar findings ([12, 13]; see online Milestone 18: The microbiota-79 80 gut-brain axis in Nature Milestones in Human Microbiota Research: https://www.nature.com/immersive/d42859-019-00041-z/index.html). Since then, several 81 studies have demonstrated that the gut microbiota modulate a wide-range of 82 neurodevelopmental processes, including blood-brain barrier (BBB) formation and integrity 83 [14], microglial maturation and function [15, 16], and myelination [17-19], as well several 84 complex behaviors (see Refs. [20, 21]). One important concept that has emerged from these 85 preclinical studies is that certain influences of the gut microbiota on the brain are sex 86 87 specific [22]. Other studies showed that gut bacteria influence behavioral abnormalities and associated brain pathology in animal models of neurodevelopmental and psychiatric 88 89 disorders [23-25]. These preclinical and other clinical findings lent support to the hypothesis that gut microbiota may also influence the development of the human brain, and that its 90 91 disruption could contribute to the pathogenesis of these disorders [25, 26].

92

93 It is now increasingly recognized that neurodevelopmental disorders such as autism 94 spectrum disorder (ASD) are often co-morbid with gastrointestinal (GI) problems. For 95 example, children with ASD have been reported to be six to eight times more likely to suffer 96 from one or more chronic GI problems than typically developing children [27]. These GI 97 issues include frequent abdominal pain, diarrhea, constipation, gaseousness, and painful stooling. Moreover, some studies have found a strong positive association of autism severity 98 99 with GI dysfunction [28, 29]. These associations of ASD with increased prevalence of GI 100 issues and reports of altered gut bacterial composition in this population motivate further 101 explorations into the precise molecular mechanisms mediating the crosstalk between the gut microbiota and the developing brain [26, 30]. The gut microbiota contains trillions of 102 bacteria which are source of a diverse peptidoglycome, bacterial peptidoglycan motifs that 103

are shed from the cell wall as bacteria divide [31, 32]. In this review, we highlight the emerging evidence supporting novel roles for bacterial peptidoglycans (PGN; a unique and essential component of the bacterial cell wall that is absent in eukaryotic cells) in neurodevelopment and behavior, after a general overview of key biological signaling pathways implicated in the microbiota-gut-brain axis. Finally, we discuss how alterations in the PGN signaling pathways early in life could impact neurodevelopmental trajectories and increase risk for neurodevelopmental disorders.

111

112 Biological signaling pathways in the microbiota-gut-brain axis

It has long been known that a complex bidirectional communication network exits between 113 the gut and the central nervous system (CNS), referred to as the gut-brain axis. This network 114 includes the sympathetic and parasympathetic branches of the autonomic nervous system, 115 the enteric nervous system, neuroendocrine and neuroimmune pathways. In recent 116 117 decades, the gut microbiota has been recognized as an important "third component" to the gut-brain axis, thus leading to the new concept of the microbiota-gut-brain axis. However, 118 119 the precise molecular mechanisms mediating interactions between gut microbes and the brain have yet to be clearly defined. Emerging evidence suggests the involvement of multiple 120 121 potential direct and indirect pathways (Figure 1), including signals carried by neuronal circuits (e.g., bidirectional vagus nerve-to-brain communication, and the enteric nervous 122 system), activation of immune responses (e.g., cytokine and chemokine release within the 123 124 gut or elsewhere that subsequently influence the brain), gut hormone signaling, tryptophan 125 metabolism, and the production of microbial metabolites that indirectly or directly influence 126 the brain, including bacterial fermentation metabolic by-products, such as short chain fatty acids (SCFAs; propionate, butyrate and acetate) (see Ref. [33]). 127

128

Undoubtedly, one of the most direct routes for the microbiota to communicate with the brain is through the vagus nerve [34]. Studies have shown that several probiotics (beneficial bacteria that produce health outcomes such as *Bifidobacterium* and *Lactobacillus* families, which do not possess pro-inflammatory lipopolysaccharide chains) utilize the vagus nerve signaling to communicate with the brain and influence behavior [35]. For example, the beneficial effects of *Lactobacillus (L.) rhamnosus* JB1 on stress-induced anxiety- and depression-related behavior are abolished by vagotomy [36]. Similarly, the vagus nerve is a Trends in Molecular Medicine

136 central gut-brain communication pathway by which L. reuteri MM4-1A rescue social deficits in several mouse models of ASD, including a genetic model (Shank3B mutant mice) [37], 137 three environmental models (valproic acid, GF and maternal high-fat diet) [37, 38], and an 138 idiopathic model (BTBR T+ Itpr3tf/J) of ASD [37]. However, the precise mechanisms by which 139 L. reuteri interacts with the vagus nerve is not fully understood. It has recently been 140 141 discovered that sensory cells from the GI tract with a primary endocrine function (enteroendocrine cells; referred to as neuropods) possess axon-like basal processes that 142 form synapses with vagal afferents [39]. Therefore, it will be interesting to explore whether 143 144 the actions of probiotics such as *L. reuteri* involve signaling through the neuropods. A recent optogenetic study showed that activation of gut-innervating vagal sensory ganglion neurons 145 can also modulate reward-relating behavior (e.g., self-stimulation behavior and conditioned 146 place preference) and dopamine release from the substantial nigra in mice, indicating that 147 148 the vagal-gut-to brain axis is also an important component of the brain reward system [40].

149

In recent years, there has been a keen interest in the role of SCFAs since they exert many 150 151 beneficial effects on host physiology (e.g., they enhance the integrity of the intestinal epithelial barrier and protect against inflammation) [41]. As SCFAs can interact with the gut-152 153 brain axis through several different mechanisms including the modulation of host chromatin structure and gene transcription as well as the activation of G-protein-couple receptors, 154 155 exposure to these bacterial metabolites during critical time windows of development might 156 have important implications for early-life programming of the brain and behavior. So far, 157 there is evidence that acetate can cross the BBB at physiological levels [42], but it is unclear 158 to what extend propionate and butyrate cross into the brain. Nevertheless, some studies have demonstrated that SCFA butyrate can restore the integrity of the BBB and that a mix of 159 160 SCFAs can reverse aberrant microglia phenotypes in adult GF mice [14], indicating that SCFAs may be one of the signaling pathways by which bacteria modulate the brain. Several 161 commensal bacteria have also been shown to produce neurotransmitters such as dopamine, 162 serotonin, and metabolites that enter circulation and exert a range of consequences outside 163 164 the GI tract [43]. With regard to the brain, a new study has shown that direct metabolites of 165 the gut microbiome (e.g., imidazole propionate) or products of the combinatorial metabolism between the microbiome and host (e.g., 3-indoxyl-sulfate, trimethylamine-N-166 oxide, and phenylacetylglycine) are present in the forebrains of healthy mice as early as the 167

168 neonatal period and remain into adulthood [44]. However, the role of these metabolites in 169 neurodevelopment remain poorly understood. Recently, studies have raised the possibility 170 that bacterial-derived products such as PGN might directly affect the developing brain and 171 behavior through central activation of pattern recognition receptors (PRRs) of the innate 172 immune system [45].

173

Pattern recognition receptors as potential key regulators of gut microbiota-brain interactions

There is growing recognition that PRRs have been adapted to mediate roles far beyond 176 innate immunity, including host homeostasis and development [46]. PRRs are a series of 177 germline-encoded host sensors that recognize highly conserved microbial molecular 178 179 signatures or "motifs" such as bacterial surface molecules (e.g., PGN), often referred to as microbe- or pathogen-associated molecular patterns (MAMPs or PAMPs). Included among 180 181 several important PRRs of the innate immune system are membrane-bound Toll-like receptors (TLRs; [47, 48]), cytosolic NOD-like receptors (nucleotide-binding domain leucine-182 183 rich repeat containing receptors; Nod1 and Nod2 receptors, [49, 50]) and PGN recognition proteins (PGRPs, Pglyrp1-4; [51, 52]). Traditionally, the expression and function of PRRs have 184 185 been investigated in the context of pathogenic microorganisms. However, the microbial motifs that activate PRRs are not restricted to pathogens, since they include structural 186 187 molecules such as lipopolysaccharide, a component of the outer membrane of Gram-188 negative bacteria, and PGN, common to almost all bacterial cell walls ([46]; Figure 2).

189

190 There is evidence from both invertebrates and vertebrates that motifs derived from 191 commensal bacteria interact with PRRs to promote developmental processes and maintain 192 homeostasis of the host [53]. For example, bacterial motifs have been implicated in the 193 regression of a juvenile-specific epithelium that facilitates the colonization of the Hawaiian 194 squid by the marine symbiotic bacterium Vibrio fischeri, which provides luminescence to the squid (Figure 3A) [54]. Moreover, the maturation of mammalian gut associated lymphoid 195 196 tissues (i.e., isolated lymphoid follicles; ILFs) is triggered by the exposure of intestinal 197 epithelial cells to PGN motifs derived from commensal Gram-negative bacteria during postnatal life, thus leading to the activation of the cytoplasmic PRR Nod1 and secretion of 198 factors that stimulate the proliferation of isolated ILFs (Figure 3B) [7, 55]. Furthermore, 199

200 accumulating data indicate that PGN motifs from commensal bacteria can also diffuse through the epithelial barrier in the intestine and reach the systemic circulation. A seminal 201 study by Clarke and colleagues showed that gut microbiota is a source of PGN that 202 systemically primes the innate immune system [56]. Specifically, these authors showed 203 translocation of the meso-diaminopimelic acid (meso-DAP)-type PGN from non-pathogenic 204 205 Gram-negative bacteria from the intestinal mucosa to neutrophils in the bone marrow of mice. The activation of the cytoplasmic PRR Nod1 by meso-DAP-type PGN was sufficient to 206 207 prime and restore neutrophil function in the bone marrow of mice with a manipulated microbiota (i.e., GF condition or antibiotic treated mice), thus revealing a previously 208 undescribed role for PGN in priming systemic innate immunity in the absence of infection 209 (Figure 3C). Other groups have recently detected traces of various PGN fragments in fetal 210 211 bovine serum (the most widely used serum-supplement for in vitro cell culture) and serum of healthy mice [57], suggesting that a homeostatic function of PGN signaling may have been 212 213 previously underappreciated.

214

215 A new antibody-based detection assay for the PGN muramyl-L-alanyl-D-isoglutamine (MDP) was described recently. The authors showed that this PGN monomer is ubiquitously present 216 217 in serum or plasma of healthy humans, rodents and non-human primates [58]. It should be noted that a wide concentration range of MDP levels were found in healthy individuals from 218 European or Asian ancestry. Approximately 75 % of all individuals had a range between 0.16-219 1 μ g/ml, 22.5% between 1-4 ug/ml and at the extreme end of the spectrum either very high 220 221 levels (4-5 ug/ml) or below the level of detection (see Figure 2d in Ref. [58]). However, 222 patients suffering from autoimmune diseases (i.e., rheumatoid arthritis and systemic lupus erythematosus) had higher levels of circulating MDP than healthy controls, thus raising the 223 224 possibility that disturbance of equilibria between PGN motifs and their sensing PRRs could 225 contribute to host pathologic states. This finding is consistent with earlier work from Laman 226 and colleagues showing the presence of antibodies specific for PGN in the cerebral spinal 227 fluid (CSF) of patients with active multiple sclerosis (MS), and inflammatory demyelinating 228 disease of the CNS [59]. For further details about the roles of PGN as driver of chronic brain 229 inflammation in MS and its experimental autoimmune encephalomyelitis models, see a 230 recent review by the latter authors [60].

Bacterial PGN motifs can be translocated into the brain and sensed by innate immunePRRs

The notion that bacterial products derived from microbiota could influence brain functions is 234 not new [61, 62]. In fact, several decades ago, it was shown that some MDP-type PGN induce 235 236 prolonged (6-12 h) increases in slow-wave sleep (SWS) in rabbits, rats and monkeys, and 237 enhanced amplitude of EEG slow waves (0.5-4.0 Hz) during bouts of SWS. Of note, the somnogenic properties of muramyl peptides are dependent upon the precise biochemical 238 239 structure (see Refs. [63, 64]), and can be distinguished from other activities of muramyl 240 peptides such as induction of fever and adjuvant activity (see Ref. [61]). Moreover, PGN fragments were detected in the CSF and urine of patients with sleep disorders [65, 66], thus 241 242 implicating PGN in the pathophysiology of sleep disorders. New scientific discoveries 243 showing a previously unappreciated complexity of the human microbiome and its wide-244 ranging impact on host health and disease has triggered a re-evaluation of the possible role 245 of microbial molecules and metabolites on host tissues, including the brain. Recently, Arentsen and colleagues showed the presence of PGN fragments in the serum of healthy 246 247 juvenile mice (i.e., specific-pathogen-free mice; see also Figure 2e in Ref. [58]). PGN levels in the serum of juvenile GF mice were found to be very low or at the limits of detection, 248 249 confirming that microbiota is the main source of PGN in the circulation. The same authors showed the presence of PGN fragments in the normal developing mouse brain, which 250 251 increases in parallel with the postnatal bacterial colonization processes ([45]; Figure 4A). It 252 was also demonstrated that two families of PRRs that specifically detect PGN [i.e., PGN-253 recognition proteins (PGRPs) and NOD-like receptors] and the PGN transporter PepT1 are 254 highly expressed in the developing brain during distinct windows of postnatal mouse development. These findings raise the possibility that PGN motifs (for example, muramyl 255 256 dipeptides and mesoDAP-type PGN) may differentially affect brain development depending 257 upon the postnatal age. At least two PGN-sensing molecules (Pglyrp2 and Nod1) have been 258 found to be highly expressed in neurons in several brain regions including the prefrontal cortex, hippocampus and cerebellum, thus indicating potential direct effects of PGN on 259 260 neurons ([45]; Figure 4B). Interestingly, the peak expression of Nod1 receptors coincides 261 with the period of synaptogenesis in rodents. These molecules are also expressed in astrocytes and microglia (albeit at lower levels than in neurons). In addition, oligodendrocyte 262 development and maturation may be affected by PGN since they express some PGN-sensing 263

264 molecules such as Nod1, according to an open access database containing transcriptomic 265 datasets from oligodendrocytes from different developmental stages (https://ki.se/en/mbb/oligointernode). It is worthwhile pointing out that the expression of 266 PGN-sensing molecules (PGRP1-4, Nod1, Nod2, Tlr2, PepT1) is highly sensitive to 267 manipulations of the gut microbiota (*i.e.*, GF condition and perinatal antibiotic exposure) 268 269 within the developing brain [45]. Moreover, there are brain region-dependent and sexdependent differences in the expression of PGN-sensing molecules during postnatal brain 270 271 development. Interestingly, these differences appear to be more pronounced in the prefrontal cortex, a key region implicated on a broad range of neurodevelopmental and 272 psychiatric disorders [67]. Taken together, these findings suggest that a highly dynamic and 273 sensitive period exists, during which postnatal microbial gut colonization can influence 274 275 developmental brain trajectories in an age-, region- and sex-specific manner via PGN 276 signaling.

277

278 Emerging roles of PGN-sensing molecules on brain development, function and behavior

279 There is a growing body of literature demonstrating that classical peripheral immune molecules can have important roles in the CNS under normal physiological conditions. For 280 281 instance, the major histocompatibility complex (MHC) class I and the pairedimmunoglobulin-like receptor B (PirB; an MHCI-binding receptor) have been implicated in 282 synaptic plasticity, learning and memory [68-70]. Moreover, some members of the TLR 283 family have been shown to modulate key neurodevelopmental processes (e.g., neurite 284 285 outgrowth, neuronal proliferation/differentiation, and neuronal cell death) and behavior 286 [71-77]. Emerging evidence also points to novel roles for PGN-sensing molecules (that is 287 PGRPs and NOD-like receptors) in the CNS [78]. The first known function of a PGN-sensing 288 molecule in the CNS came from the Drosophila model system [79]. The authors 289 demonstrated that a member of the PGRP family (PGRP-LC) is expressed at the presynaptic 290 terminal of Drosophila motor neurons. This PGN-sensing molecule plays a key role in the 291 induction and sustained expression of presynaptic homeostatic plasticity; thus, it controls 292 the homeostatic modulation of the readily releasable pool of synaptic vesicles following inhibition of postsynaptic glutamate receptor function. 293

295 In mammals, there are four PGRPs including a "long" isoform (Pglyrp2 or PGRP-L) that is a Nacetylmuramoyl-l-alanine amidase that hydrolyzes the amide bond between MurNAc and l-296 Ala of bacterial PGN (which is unique among the mammalian PGRPs) [52]. In mice, Pglyrp2 is 297 highly expressed in the brain (e.g., prefrontal cortex, striatum, hippocampus and cerebellum) 298 during the first few days of life [45]. In line with this, human PGLYRP2 protein has also been 299 300 detected in postmortem cerebral cortex tissue of a young child, but not in most adult cortical tissues [i.e., moderate to strong labelling in the neuropil and glial cells, respectively; 301 302 the Human Protein Atlas; (https://www.proteinatlas.org/) [80]]. In a recent study, it was 303 demonstrated that Pglyrp2 knockout (KO) mice have an altered expression of the ASD risk gene c-Met, and BDNF (brain-derived neurotrophic factor) [45], both implicated in the 304 formation and modulation of brain circuits [81, 82]. Moreover, juvenile Pglyrp2 KO mice 305 306 display a significant increase in social interaction levels toward an unfamiliar stimuli mouse, 307 without any alterations in anxiety-like behavior or motor activity [45]. Interestingly, this 308 phenotype was more pronounced in male offspring. In another study, the same authors 309 demonstrated that the absence of Pglyrp2 leads to major sex-dependent alterations in 310 motor and anxiety-like behavior later in adulthood (i.e., 15 month-old mice) [83]. In this case, Pglyrp2-deficient female mice, but not males, show better motor performance. 311 312 However, they display increased levels of anxiety-like behavior, suggesting that the modulatory effects of Pglyrp2 in the brain are highly dependent upon multiple host factors 313 314 including age, sex and type of neuronal circuits. Peptidoglycan recognition protein 1 315 (Pglyrp1, also known as tag7 protein or PGRP-S) is another member of the mammalian PGRP 316 family that is expressed in the brain. Unlike Pglyrp2, the expression of Pglyrp1 peaks around 317 the second week of postnatal life and continues to be expressed into adulthood [45]. Previous work has shown that PGRP1 mRNA levels increase in brain stem and hypothalamus 318 319 after sleep deprivation in rodents [84], suggesting a possible role for this PGN-sensing 320 molecule in homeostatic regulation of sleep. However, studies using more advanced 321 transgenic mouse models (e.g., conditional brain-specific knockdown of Pglyrp2) are 322 fundamental to unravel the specific role of PGRPs in the CNS.

323

Recently, Pusceddu and colleagues provided the first experimental evidence implicating the NOD-like receptors in the regulation of the stress response, serotonin (5-HT) signaling and behavior [85]. Specifically, these authors showed that NodDKO mice deficient in both Nod1

327 and Nod2 exhibit signs of stress-induced anxiety-like behavior, cognitive impairment and depressive-like behavior under conditions of a hyperactive HPA axis, but not under baseline 328 conditions. Surprisingly, no major sex differences were found. Moreover, these authors 329 identified the central 5-HT system as one potential neural substrate mediating the 330 behavioral phenotype of NodDKO mice. In fact, NodDKO mice had lower levels of 5-HT in 331 332 both the hippocampus and brain stem under basal conditions. In addition, the expression profile of several key components of the 5-HT signaling pathways such as tryptophan 333 hydroxylase 2 (the rate limiting enzyme for 5-HT synthesis), the 5-HT receptor 1a (which 334 regulates 5-HT release) and the 5-HT transporter were impaired after exposure to stress. 335 Importantly, these authors showed that the stress-induced behavioral impairments 336 observed in NodDKO mice could be restored by chronic treatment with a 5-HT reuptake 337 338 inhibitor (fluoxetine). Another important finding of this study was that intestinal epithelial cell (IEC)-specific ablation of Nod1 (VilCre+Nod1f/f), but not Nod2 receptors, resulted in 339 340 stress-induced impairments in cognitive function and anxiety-like behavior. The latter observations highlight a novel role for the IEC Nod1 receptors in behavioral responses to 341 342 stress and identify this PGN-sensing molecule as potential new target for the treatment of stress-associated gut-brain disorders. However, the specific roles of NOD-like receptors 343 344 within the brain remain to be further clarified. Previous studies have shown that murine microglia express robust levels of Nod2 mRNA and protein, but little or no expression of 345 Nod1 [86, 87]. On the other hand, Nod1 protein is highly expressed in developing neurons 346 347 across multiple brain regions including the prefrontal cortex, hippocampus and cerebellum 348 (see supplementary figure 3 in Ref. [45]). Both Nod1 and Nod2 are moderately expressed in 349 astrocytes [45, 87]. These findings raise the possibility that Nod1 and Nod2 may have distinct 350 functions in glia and neurons of the adult and developing brain.

351

352 Potential role of PGN in the Pathophysiology of Neurodevelopmental Disorders

It is now widely recognized that the maternal-fetal environment plays a crucial role in the development of the fetal brain and long-term neurodevelopmental trajectories, including susceptibility to mental health disorders in childhood and adulthood [88]. Indeed, epidemiological studies have shown an association between maternal infection/ inflammation during pregnancy and increased risk for neurodevelopmental and psychiatric disorders such as ASD [89-92]. These findings are supported by experimental mouse studies 359 demonstrating that maternal immune activation during pregnancy (MIA; through exposure 360 to microbial pathogens or pro-inflammatory PAMPs) induces ASD-like behavioral traits in their offspring [93, 94]. Recent work by Choi, Huh and colleagues have demonstrated that 361 MIA promotes abnormal cortical development and ASD-like behavioral phenotypes in mouse 362 offspring through the activation of the maternal T helper 17 cell-interleukin-17a (IL-17a) 363 364 pathway [95]. These authors discovered that MIA-induced phenotypes in mouse offspring require commensal maternal gut bacteria (i.e., segmented filamentous bacteria; SFB) that 365 366 promote Th17 cell differentiation [96]. For instance, pregnant C57BL/6 mice, which are colonized with SFB and contain higher numbers of gut Th17 cells were more susceptible to 367 MIA-induced behavioral and morphological pathology. Conversely, pregnant C57BL/6 mice 368 which are not colonized by SFB and lack gut Th17 cells were not susceptible. These findings 369 370 suggest that the composition of the maternal gut microbiota is an important contributing risk factor for MIA-induced behavioral abnormalities in offspring. Indeed, mounting evidence 371 372 identifies the maternal gut microbiota as a common denominator by which a broad range of 373 environmental risk factors such as diet (e.g., high-fat diet), infections, antibiotic exposure 374 and stress can affect both the maternal health and fetal development [9, 97, 98]. The developing fetus receives oxygen and nutrients along other bioactive compounds from the 375 376 maternal circulation, and therefore, alterations in the composition and metabolic activity of maternal gut microbiota could profoundly influence prenatal brain development processes 377 (e.g., neurogenesis, migration, and differentiation) and subsequent neurodevelopmental 378 379 outcomes. In line with this notion, a new study in mice demonstrated that during normal 380 pregnancy, SCFAs from the commensal maternal gut microbiota can reach the developing 381 embryo and promote the differentiation of sympathetic neurons via activation of GPR41 [99]. Moreover, studies demonstrating disrupted BBB maturation and an altered microglial 382 383 transcriptome profile in GF mice during prenatal life underscores the importance of the 384 commensal maternal microbiome during fetal brain development [14, 16].

385

Recently, it has been proposed that MAMPs such as PGN could be an important mediator of host-microbiome interactions at the maternal-fetal interface since PGN reaches the systemic circulation not only during bacterial infections, but also during normal physiological conditions [78]. In line with this notion, a recent study showed that components of the bacterial cell wall (*i.e.*, PGN-teichoic acid complex of *Streptococcus pneumoniae*, a major Trends in Molecular Medicine

391 pathogen causing infections such as meningitis) can traverse the placental barrier through the platelet activating factor receptor (PAFr) and affect the developing mouse fetal brain 392 [100]. This PGN-teichoic acid complex induces the transcription factor FoxG1 in the fetal 393 neocortex via the activation of the Tlr2, resulting in a 50% greater density of neurons in the 394 cortical plate. This abnormal neuroproliferation was associated with abnormal cognitive 395 396 development. Intriguingly, a TIr-2-dependent response to this PAM did not induce inflammation in the fetal brain. Recently, it was reported that NOD1, NOD2, TLR2, as well as 397 398 the putative PGN transporters PEPT2 and PAFr are abundantly expressed in the human placenta [78]. These findings suggest that bacterial PGN motifs from the maternal 399 commensal gut microbiota may also be capable of influencing the developing brain, and that 400 disruption of components of this signaling pathway could lead to abnormal motor, social, 401 402 and cognitive development (Figure 5).

403

In humans, accelerated brain growth in infancy has been associated with a broad range of 404 405 developmental delays in motor, language, and cognitive functions [101, 102]. For instance, 406 neurodevelopmental disorders, including ASD, have been associated with atypical brain connectivity patterns involving higher-order association neocortical regions [103-105]. A 407 408 large proportion of high-confidence ASD-associated risk genes are pleiotropic, and affect proliferation/differentiation and/or synapse development in the neocortex, amygdala, 409 hippocampus, striatum and cerebellum, supporting the notion that ASD begins during 410 411 prenatal life [106]. It will therefore be of great interest to investigate the potential link 412 between maternal circulating PGN levels during pregnancy, and social-cognitive 413 development of infants, as well as potential novel associations between genetic variants in 414 PGN-sensing molecules and ASD ([107]; see Clinician's Corner).

415

416 Concluding Remarks

Recent discoveries showing an unprecedented role for the commensal gut microbiota in the regulation of brain development and behavior has triggered a paradigm shift in our conceptualization of the origin of human brain disorders. The current focus of this new microbiome-gut-brain axis field is to delineate the precise molecular mechanisms and signaling pathways employed by commensal gut bacteria to influence the brain. PRRs that recognize bacterial surface molecules, such as PGN, have emerged as potential novel 423 mediators of microbiota-gut-brain axis signaling. The gut microbiota contains trillions of commensal bacteria producing a diverse peptidoglycome that can disseminate systemically 424 and reach peripheral organs such as the brain. PRRs that specifically recognize PGN (i.e., 425 PGN-sensing molecules; NOD-like receptors and PGN-recognition proteins), and the PGN 426 transporter PepT1 are highly expressed in the developing brain during specific windows of 427 428 postnatal development. Emerging evidence suggests crucial roles for PGN-sensing molecules in the regulation of social behavior and anxiety, and behavioral responses to stress. Despite 429 430 recent advances, many questions remain to be answered, including the characterization of the specific types of PGN that can cross the BBB under physiological conditions, and how 431 they are transported into brain cells (neurons, astrocytes, microglia and oligodendrocytes 432 (see Outstanding Questions). It is worthwhile acknowledging that the laboratory of 433 434 Gomperts Boneca at the Institut Pasteur in Paris has been advancing some of these questions by combining different PGN labelling methods with advanced imaging and genetic 435 436 approaches (see abstracts from the Great Wall Symposium 2019, September 25-27, 2019). From a clinical perspective, it would be of great importance to determine whether serum or 437 438 plasma levels of PGN motifs during pregnancy and/ or early postnatal life could help to identify infants and children at risk for atypical social and cognitive development. It would be 439 440 equally important to identify potential genetic risk variants involved in the sensing of bacterial-derived products (e.g., by creating a polygene risk scores of key genes involved in 441 PGN-sensing molecules) that are associated with atypical neurodevelopmental trajectories. 442 443 This could be accomplished in a multicenter, prospective, longitudinal study of infants at 444 high- and low-risk for atypical brain development such as ASD. In parallel, investigate 445 potential effects of PGN motifs on early aspects of human brain prenatal development by taking advantage of human induced pluripotent stem cells technology, which allows the 446 447 generation of personalized neurons or glial cells. This information will provide key mechanistic insight into how PGN can influence brain development, function and behavior, 448 449 as well as novel potential therapeutic targets for the treatment of neurodevelopmental and psychiatric disorders, often associated with co-morbid gastrointestinal problems and altered 450 451 gut microbiota composition.

452

453 Acknowledgments

- 454 The authors apologize to colleagues whose publications were not cited due to space
- 455 constraints and the special focus on recent work. Work from the Diaz Heijtz laboratory cited
- 456 in this review has been supported by grants from the Swedish Research Council, Swedish
- 457 Brain Foundation, Olle Engkvist Byggmästare Foundation and the Frimurare Barnhus
- 458 Foundation. All figures were partially created using BioRender (<u>https://biorender.com</u>).
- 459

460 **References**

- 461 1. Dominguez-Bello, M.G. et al. (2019) Role of the microbiome in human development. Gut 68 (6),462 1108-1114.
- 463 2. Sender, R. et al. (2016) Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to 464 Host Cells in Humans. Cell 164 (3), 337-40.
- 3. Tierney, B.T. et al. (2019) The Landscape of Genetic Content in the Gut and Oral Human
- 466 Microbiome. Cell Host Microbe 26 (2), 283-295 e8.
- 467 4. Qin, J. et al. (2010) A human gut microbial gene catalogue established by metagenomic
- 468 sequencing. Nature 464 (7285), 59-65.
- 5. Cho, I. and Blaser, M.J. (2012) The human microbiome: at the interface of health and disease. NatRev Genet 13 (4), 260-70.
- 471 6. Rowland, I. et al. (2018) Gut microbiota functions: metabolism of nutrients and other food
- 472 components. Eur J Nutr 57 (1), 1-24.
- 473 7. Al Nabhani, Z. and Eberl, G. (2020) Imprinting of the immune system by the microbiota early in life.
 474 Mucosal Immunol 13 (2), 183-189.
- 475 8. Borre, Y.E. et al. (2014) Microbiota and neurodevelopmental windows: implications for brain
- 476 disorders. Trends Mol Med 20 (9), 509-18.
- 9. Diaz Heijtz, R. (2016) Fetal, neonatal, and infant microbiome: Perturbations and subsequent effects
 on brain development and behavior. Semin Fetal Neonatal Med 21 (6), 410-417.
- 479 10. Sudo, N. et al. (2004) Postnatal microbial colonization programs the hypothalamic-pituitary-
- 480 adrenal system for stress response in mice. J Physiol 558 (Pt 1), 263-75.
- 481 11. Diaz Heijtz, R. et al. (2011) Normal gut microbiota modulates brain development and behavior.
 482 Proc Natl Acad Sci U S A 108 (7), 3047-52.
- 483 12. Neufeld, K.M. et al. (2011) Reduced anxiety-like behavior and central neurochemical change in
 484 germ-free mice. Neurogastroenterol Motil 23 (3), 255-64, e119.
- 485 13. Clarke, G. et al. (2013) The microbiome-gut-brain axis during early life regulates the hippocampal
- 486 serotonergic system in a sex-dependent manner. Mol Psychiatry 18 (6), 666-73.
- 487 14. Braniste, V. et al. (2014) The gut microbiota influences blood-brain barrier permeability in mice.
- 488 Sci Transl Med 6 (263), 263ra158.
- 489 15. Erny, D. et al. (2015) Host microbiota constantly control maturation and function of microglia in
 490 the CNS. Nat Neurosci 18 (7), 965-77.
- 491 16. Thion, M.S. et al. (2018) Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific
 492 Manner. Cell 172 (3), 500-516 e16.
- 493 17. Gacias, M. et al. (2016) Microbiota-driven transcriptional changes in prefrontal cortex override494 genetic differences in social behavior. Elife 5, e13442.
- 495 18. Hoban, A.E. et al. (2016) Regulation of prefrontal cortex myelination by the microbiota. Transl496 Psychiatry 6, e774.
- 497 19. Radulescu, C.I. et al. (2019) Manipulation of microbiota reveals altered callosal myelination and
- 498 white matter plasticity in a model of Huntington disease. Neurobiol Dis 127, 65-75.
- 20. Lynch, J.B. and Hsiao, E.Y. (2019) Microbiomes as sources of emergent host phenotypes. Science
 365 (6460), 1405-1409.

- 501 21. Sherwin, E. et al. (2019) Microbiota and the social brain. Science 366 (6465).
- 502 22. Jaggar, M. et al. (2020) You've got male: Sex and the microbiota-gut-brain axis across the lifespan.
 503 Front Neuroendocrinol 56, 100815.
- 504 23. Needham, B.D. et al. (2018) Searching for the gut microbial contributing factors to social behavior 505 in rodent models of autism spectrum disorder. Dev Neurobiol 78 (5), 474-499.
- 506 24. Hsiao, E.Y. et al. (2013) Microbiota modulate behavioral and physiological abnormalities
- 507 associated with neurodevelopmental disorders. Cell 155 (7), 1451-63.
- 508 25. Lum, G.R. et al. (2020) Emerging roles for the intestinal microbiome in epilepsy. Neurobiol Dis509 135, 104576.
- 510 26. Vuong, H.E. and Hsiao, E.Y. (2017) Emerging Roles for the Gut Microbiome in Autism Spectrum
 511 Disorder. Biol Psychiatry 81 (5), 411-423.
- 512 27. Chaidez, V. et al. (2014) Gastrointestinal problems in children with autism, developmental delays
- 513 or typical development. J Autism Dev Disord 44 (5), 1117-27.
- 514 28. Adams, J.B. et al. (2011) Gastrointestinal flora and gastrointestinal status in children with autism--
- 515 comparisons to typical children and correlation with autism severity. BMC Gastroenterol 11, 22.
- 516 29. Wang, L.W. et al. (2011) The prevalence of gastrointestinal problems in children across the United
- 517 States with autism spectrum disorders from families with multiple affected members. J Dev Behav
 518 Pediatr 32 (5), 351-60.
- 519 30. Srikantha, P. and Mohajeri, M.H. (2019) The Possible Role of the Microbiota-Gut-Brain-Axis in 520 Autism Spectrum Disorder. Int J Mol Sci 20 (9).
- 521 31. Wheeler, R. et al. (2014) The biology of bacterial peptidoglycans and their impact on host
- 522 immunity and physiology. Cell Microbiol 16 (7), 1014-23.
- 32. Irazoki, O. et al. (2019) Peptidoglycan Muropeptides: Release, Perception, and Functions as
 Signaling Molecules. Front Microbiol 10, 500.
- 525 33. Cryan, J.F. et al. (2019) The Microbiota-Gut-Brain Axis. Physiol Rev 99 (4), 1877-2013.
- 526 34. Fulling, C. et al. (2019) Gut Microbe to Brain Signaling: What Happens in Vagus. Neuron 101 (6), 527 998-1002.
- 528 35. Sarkar, A. et al. (2018) The Microbiome in Psychology and Cognitive Neuroscience. Trends Cogn 529 Sci 22 (7), 611-636.
- 36. Sarkar, A. et al. (2016) Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals. Trends
 Neurosci 39 (11), 763-781.
- 37. Sgritta, M. et al. (2019) Mechanisms Underlying Microbial-Mediated Changes in Social Behavior in
 Mouse Models of Autism Spectrum Disorder. Neuron 101 (2), 246-259 e6.
- 534 38. Buffington, S.A. et al. (2016) Microbial Reconstitution Reverses Maternal Diet-Induced Social and 535 Synaptic Deficits in Offspring. Cell 165 (7), 1762-1775.
- 39. Kaelberer, M.M. et al. (2018) A gut-brain neural circuit for nutrient sensory transduction. Science361 (6408).
- 40. Han, W. et al. (2018) A Neural Circuit for Gut-Induced Reward. Cell 175 (3), 665-678 e23.
- 539 41. Silva, Y.P. et al. (2020) The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain
 540 Communication. Front Endocrinol (Lausanne) 11, 25.
- 541 42. Frost, G. et al. (2014) The short-chain fatty acid acetate reduces appetite via a central
- 542 homeostatic mechanism. Nat Commun 5, 3611.
- 43. Caspani, G. and Swann, J. (2019) Small talk: microbial metabolites involved in the signaling frommicrobiota to brain. Curr Opin Pharmacol 48, 99-106.
- 545 44. Swann, J.R. et al. (2020) Developmental Signatures of Microbiota-Derived Metabolites in the546 Mouse Brain. Metabolites 10 (5).
- 45. Arentsen, T. et al. (2017) The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain
 development and behavior. Mol Psychiatry 22 (2), 257-266.
- 549 46. Chu, H. and Mazmanian, S.K. (2013) Innate immune recognition of the microbiota promotes host-550 microbial symbiosis. Nat Immunol 14 (7), 668-75.
- 551 47. Beutler, B. (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature
- 552 430 (6996), 257-63.

- 48. Moresco, E.M. et al. (2011) Toll-like receptors. Curr Biol 21 (13), R488-93.
- 49. Philpott, D.J. et al. (2014) NOD proteins: regulators of inflammation in health and disease. Nat
 Rev Immunol 14 (1), 9-23.
- 556 50. Mukherjee, T. et al. (2019) NOD1 and NOD2 in inflammation, immunity and disease. Arch 557 Biochem Biophys 670, 69-81.
- 558 51. Royet, J. and Dziarski, R. (2007) Peptidoglycan recognition proteins: pleiotropic sensors and 559 effectors of antimicrobial defences. Nat Rev Microbiol 5 (4), 264-77.
- 560 52. Royet, J. et al. (2011) Peptidoglycan recognition proteins: modulators of the microbiome and 561 inflammation. Nat Rev Immunol 11 (12), 837-51.
- 562 53. McFall-Ngai, M. et al. (2013) Animals in a bacterial world, a new imperative for the life sciences.
 563 Proc Natl Acad Sci U S A 110 (9), 3229-36.
- 564 54. McFall-Ngai, M. et al. (2010) The role of the immune system in the initiation and persistence of 565 the Euprymna scolopes--Vibrio fischeri symbiosis. Semin Immunol 22 (1), 48-53.
- 566 55. Bouskra, D. et al. (2008) Lymphoid tissue genesis induced by commensals through NOD1 567 regulates intestinal homeostasis. Nature 456 (7221), 507-10.
- 568 56. Clarke, T.B. et al. (2010) Recognition of peptidoglycan from the microbiota by Nod1 enhances 569 systemic innate immunity. Nat Med 16 (2), 228-31.
- 570 57. Molinaro, R. et al. (2019) Trace levels of peptidoglycan in serum underlie the NOD-dependent 571 cytokine response to endoplasmic reticulum stress. J Biol Chem 294 (22), 9007-9015.
- 572 58. Huang, Z. et al. (2019) Antibody neutralization of microbiota-derived circulating peptidoglycan
- 573 dampens inflammation and ameliorates autoimmunity. Nat Microbiol 4 (5), 766-773.
- 574 59. Schrijver, I.A. et al. (2001) Bacterial peptidoglycan and immune reactivity in the central nervous 575 system in multiple sclerosis. Brain 124 (Pt 8), 1544-54.
- 60. Laman, J.D. et al. (2020) Bacterial peptidoglycan as a driver of chronic brain inflammation. TrendsMol Med, In Press.
- 578 61. Krueger, J.M. and Opp, M.R. (2016) Sleep and Microbes. Int Rev Neurobiol 131, 207-225.
- 579 62. Kubota, K. (1989) Kuniomi Ishimori and the first discovery of sleep-inducing substances in the
- 580 brain. Neurosci Res 6 (6), 497-518.
- 581 63. Johannsen, L. et al. (1994) Somnogenic activity of muramyl peptide-derived immune adjuvants.
- 582 Int J Immunopharmacol 16 (2), 109-16.
- 583 64. Johannsen, L. et al. (1989) Somnogenic activity of O-acetylated and dimeric muramyl peptides.
 584 Infect Immun 57 (9), 2726-32.
- 585 65. Krueger, J.M. et al. (1982) The composition of sleep-promoting factor isolated from human urine.
 586 J Biol Chem 257 (4), 1664-9.
- 587 66. Martin, S.A. et al. (1984) Peptidoglycans as promoters of slow-wave sleep. I. Structure of the
- sleep-promoting factor isolated from human urine. J Biol Chem 259 (20), 12652-8.
- 589 67. Bicks, L.K. et al. (2015) Prefrontal Cortex and Social Cognition in Mouse and Man. Front Psychol 6,590 1805.
- 591 68. Boulanger, L.M. and Shatz, C.J. (2004) Immune signalling in neural development, synaptic
- 592 plasticity and disease. Nat Rev Neurosci 5 (7), 521-31.
- 69. Djurisic, M. et al. (2013) PirB regulates a structural substrate for cortical plasticity. Proc Natl Acad
 Sci U S A 110 (51), 20771-6.
- 70. Lee, H. et al. (2014) Synapse elimination and learning rules co-regulated by MHC class I H2-Db.
 Nature 509 (7499), 195-200.
- 597 71. Lathia, J.D. et al. (2008) Toll-like receptor 3 is a negative regulator of embryonic neural progenitor 598 cell proliferation. J Neurosci 28 (51), 13978-84.
- 599 72. Ma, Y. et al. (2006) Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and 600 inducer of neuronal apoptosis. J Cell Biol 175 (2), 209-15.
- 73. Okun, E. et al. (2011) Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci
 34 (5), 269-81.
- 603 74. Okun, E. et al. (2010) TLR2 activation inhibits embryonic neural progenitor cell proliferation. J
- 604 Neurochem 114 (2), 462-74.

- 75. Shechter, R. et al. (2008) Toll-like receptor 4 restricts retinal progenitor cell proliferation. J CellBiol 183 (3), 393-400.
- 76. Okun, E. et al. (2012) Evidence for a developmental role for TLR4 in learning and memory. PLoSOne 7 (10), e47522.
- 609 77. Okun, E. et al. (2010) Toll-like receptor 3 inhibits memory retention and constrains adult
- 610 hippocampal neurogenesis. Proc Natl Acad Sci U S A 107 (35), 15625-30.
- 611 78. Tosoni, G. et al. (2019) Bacterial peptidoglycans as novel signaling molecules from microbiota to
- brain. Curr Opin Pharmacol 48, 107-113.
- 79. Harris, N. et al. (2015) The Innate Immune Receptor PGRP-LC Controls Presynaptic Homeostatic
 Plasticity. Neuron 88 (6), 1157-1164.
- 615 80. Thul, P.J. et al. (2017) A subcellular map of the human proteome. Science 356 (6340).
- 616 81. Eagleson, K.L. et al. (2017) The Pleiotropic MET Receptor Network: Circuit Development and the
- 617 Neural-Medical Interface of Autism. Biol Psychiatry 81 (5), 424-433.
- 82. Park, H. and Poo, M.M. (2013) Neurotrophin regulation of neural circuit development and
 function. Nat Rev Neurosci 14 (1), 7-23.
- 620 83. Arentsen, T. et al. (2018) Sex-dependent alterations in motor and anxiety-like behavior of aged
- 621 bacterial peptidoglycan sensing molecule 2 knockout mice. Brain Behav Immun 67, 345-354.
- 622 84. Rehman, A. et al. (2001) The cloning of a rat peptidoglycan recognition protein (PGRP) and its
- 623 induction in brain by sleep deprivation. Cytokine 13 (1), 8-17.
- 85. Pusceddu, M.M. et al. (2019) Nod-like receptors are critical for gut-brain axis signalling in mice. J
 Physiol 597 (24), 5777-5797.
- 626 86. Sterka, D., Jr. and Marriott, I. (2006) Characterization of nucleotide-binding oligomerization
- 627 domain (NOD) protein expression in primary murine microglia. J Neuroimmunol 179 (1-2), 65-75.
- 628 87. Sterka, D., Jr. et al. (2006) Functional expression of NOD2, a novel pattern recognition receptor 629 for bacterial motifs, in primary murine astrocytes. Glia 53 (3), 322-30.
- 88. Al-Haddad, B.J.S. et al. (2019) The fetal origins of mental illness. Am J Obstet Gynecol 221 (6),
 549-562.
- 632 89. Lee, B.K. et al. (2015) Maternal hospitalization with infection during pregnancy and risk of autism
 633 spectrum disorders. Brain Behav Immun 44, 100-5.
- 634 90. Atladottir, H.O. et al. (2010) Maternal infection requiring hospitalization during pregnancy and
 635 autism spectrum disorders. J Autism Dev Disord 40 (12), 1423-30.
- 636 91. Bokobza, C. et al. (2019) Neuroinflammation in preterm babies and autism spectrum disorders.
 637 Pediatr Res 85 (2), 155-165.
- 638 92. Patterson, P.H. (2011) Maternal infection and immune involvement in autism. Trends Mol Med 639 17 (7), 389-94.
- 640 93. Brown, A.S. and Meyer, U. (2018) Maternal Immune Activation and Neuropsychiatric Illness: A
- Translational Research Perspective. Am J Psychiatry 175 (11), 1073-1083.
- 642 94. Estes, M.L. and McAllister, A.K. (2016) Maternal immune activation: Implications for
- 643 neuropsychiatric disorders. Science 353 (6301), 772-7.
- 644 95. Reed, M.D. et al. (2020) IL-17a promotes sociability in mouse models of neurodevelopmental
 645 disorders. Nature 577 (7789), 249-253.
- 646 96. Kim, S. et al. (2017) Maternal gut bacteria promote neurodevelopmental abnormalities in mouse 647 offspring. Nature 549 (7673), 528-532.
- 648 97. Codagnone, M.G. et al. (2019) Programming Bugs: Microbiota and the Developmental Origins of 649 Brain Health and Disease. Biol Psychiatry 85 (2), 150-163.
- 650 98. Jasarevic, E. and Bale, T.L. (2019) Prenatal and postnatal contributions of the maternal
- 651 microbiome on offspring programming. Front Neuroendocrinol 55, 100797.
- 652 99. Kimura, I. et al. (2020) Maternal gut microbiota in pregnancy influences offspring metabolic
- 653 phenotype in mice. Science 367 (6481).
- 654 100. Humann, J. et al. (2016) Bacterial Peptidoglycan Traverses the Placenta to Induce Fetal
- 655 Neuroproliferation and Aberrant Postnatal Behavior. Cell Host Microbe 19 (3), 388-99.

- 101. Courchesne, E. et al. (2001) Unusual brain growth patterns in early life in patients with autistic
 disorder: an MRI study. Neurology 57 (2), 245-54.
- 658 102. Hazlett, H.C. et al. (2005) Magnetic resonance imaging and head circumference study of brain 659 size in autism: birth through age 2 years. Arch Gen Psychiatry 62 (12), 1366-76.
- 660 103. Hahamy, A. et al. (2015) The idiosyncratic brain: distortion of spontaneous connectivity patterns 661 in autism spectrum disorder. Nat Neurosci 18 (2), 302-9.
- 662 104. Just, M.A. et al. (2012) Autism as a neural systems disorder: a theory of frontal-posterior
- underconnectivity. Neurosci Biobehav Rev 36 (4), 1292-313.
- 105. Schipul, S.E. et al. (2011) Inter-regional brain communication and its disturbance in autism.
 Front Syst Neurosci 5, 10.
- 106. Courchesne, E. et al. (2019) The ASD Living Biology: from cell proliferation to clinical phenotype.
 Mol Psychiatry 24 (1), 88-107.
- 668 107. Goldman, S.M. et al. (2014) Peptidoglycan recognition protein genes and risk of Parkinson's
 669 disease. Mov Disord 29 (9), 1171-80.
- 108. Eberl, G. and Lochner, M. (2009) The development of intestinal lymphoid tissues at the interfaceof self and microbiota. Mucosal Immunol 2 (6), 478-85.
- 109. Moore, R.E. and Townsend, S.D. (2019) Temporal development of the infant gut microbiome.
- 673 Open Biol 9 (9), 190128.
- 674 Figure legends
- 675

Figure 1. Biological signaling pathways and molecules involved in the microbiota-gut-brain 676 axis. There are multiple direct and indirect pathways through which gut microbiota may 677 678 influence the brain, including signals carried by neuronal circuits [e.g., bidirectional vagus 679 nerve-to-brain communication, the enteric nervous system and neuropods; (1)], the production of bacterial fermentation metabolic by-products, such as short chain fatty acids 680 [SCFAs; propionate, butyrate and acetate; (2)], tryptophan metabolites and 681 neurotransmitters (3), release of cytokines by immune cells [A. Dendritic cell; B. B cell; C. 682 Mast cell; D. T cell; (4)], and gut hormone signaling (5). Some of these molecules can activate 683 the vagus nerve or reach the brain via systemic circulation, and directly affect brain 684 functions. Activation of the hypothalamic-pituitary-adrenal (HPA) axis is characterized by the 685 686 release of corticotropin-releasing hormone (CRH) from the paraventricular nucleus, which then stimulates the release of adrenocorticotropic hormone (ACTH) from the anterior 687 pituitary gland. ACTH then acts on the adrenal cortex to stimulate the production and 688 release of glucocorticoids (corticosterone in rodents and cortisol in humans), which can have 689 690 a major impact on gut physiology (e.g., modulating the intestinal epithelial barrier and immune responses), and gut microbiota composition (6). The gut microbiota has been 691 shown to influence various neurodevelopmental processes such as microglial maturation 692 693 and function, blood brain barrier formation and integrity, myelination and neurogenesis (7).

694

695 Figure 2. Bacterial PGN location and structure. A. Gram-positive bacteria display a multilayered PGN 696 cell wall, which contains teichoic acids and often other polysaccharides, proteins and lipoproteins 697 (not shown). In contrast, Gram-negative bacteria have a relatively thin PGN cell wall, surrounded by 698 an outer membrane containing lipopolysaccharides (LPS). **B.** PGN is a polymer consisting of β (1-4)-699 linked N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), with all lactyl groups of 700 MurNAc substituted with stem peptides, typically containing four alternating L- and D-amino acids. 701 The stem peptides from adjacent strands are often crosslinked, either directly or through short 702 peptides. Shown are two examples of the general types of PGN, lysine-type PGN characteristic for 703 cell walls in most Gram-positive bacteria and DAP-type PGN present in Gram-negative bacteria and a 704 subset of Gram-positive bacteria. PGN motifs are recognized via a series of PRRs such as NOD-like 705 receptors. For example, an intact MurNAc moiety is essential for Nod2 recognition, which is strongly 706 activated by muramyl dipeptide (MDP). In contrast, the presence of the glycan moiety is not required 707 for Nod1 recognition as iE-DAP or Tri-DAP are sufficient for the activation of this PRR. However, Nod1 708 is also activated to meso-DAP-type PGN containing muramyl tripeptides (M-TriDAP) or tetrapeptides 709 (M-TetraDAP). In addition, M-TriDAP modified by amidation of the meso-DAP residue (DAPNH2) have 710 been shown activates Nod2 and not recognized by Nod1 receptor [31].

- 711
- 712
- 713
- 714
- 715
- 716

Figure 3. Evidence from invertebrate and vertebrate models supporting a role of PGN in the crosstalk between microbial symbionts and their hosts. **A.** Beneficial symbiotic relationship between the squid Euprymna scolopes and the luminescent bacteria Vibrio fischeri. Epithelial cells of the light organ of E. scolopes secrete mucus-containing peptidoglycan recognition protein 2 (PGRP2) that select V. fischeri from other bacterial species present in the water. V. fischeri enters through the pores into the ducts of the light organ and colonize the deep crypts, where they induce apoptosis and morphogenesis of the light organ (figure 724 modified from [52]). B. Development of isolated lymphoid follicles (ILFs) by commensal gut microbiota. Nod1 receptors in intestinal epithelial cells are activated by PGN released by the 725 gut microbiota inducing the expression of CCL20 and β-defensin-3. These factors are CC 726 727 chemokine receptor 6 (CCR6) agonists expressed on intestinal B cells and lymphoid tissue inducer (LTi) cells in cryptopatches. Activated CCR6 cause the recruitment of CCR6+ B cells to 728 729 form immature ILFs. The development of immature ILFs into mature follicles require the tumor necrosis factor- α (TNF- α) produced by dendritic cells. B cells from mature ILFs 730 731 produce IgA that modulates the composition of the gut microbiota (figure modified from [108]). C. Gut microbiota primes the bone marrow-derived neutrophils. Meso-DAP-type PGN 732 released by Gram-negative bacteria in the gut can be translocated into the systemic 733 circulation and reach the neutrophils in the bone marrow. The activation of Nod1 receptor in 734 735 the neutrophils result in their increased capacity to react against microorganisms (figure modified from [56]). 736

- 737
- 738
- 739
- 740
- 741
- 742
- 743
- 744
- 745

Figure 4. Translocation of bacterial PGN from gut microbiota to the brain. **A.** PGN motifs from the commensal gut microbiota disseminate systemically and can reach the brain. **B.** Schematic representation of blood brain barrier composed by endothelial cells of the brain capillary wall, astrocyte end-feet surrounding the capillary and pericytes embedded in the capillary basement membrane. PGN motifs can cross blood brain barrier and are sensed by

- 751 PRRs expressed in brain cells (neurons, oligodendrocytes and microglia). See main text for
- 752 further details.

- /00

Figure 5. Schematic representation of the proposed PGN dissemination from maternal microbiota to the fetal brain. **A.** PGN fragments derived from commensal maternal gut microbiota translocate from the gut lumen into the bloodstream and reach the placenta. PGN can transverse the placenta and enter the fetal brain, where it can affect key neurodevelopmental processes (e.g., proliferation, differentiation, synaptogenesis and myelination) via activation of PGN-sensing molecules of the innate immune system. **B.** PGN Trends in Molecular Medicine

signaling can be affected by host genetics (e.g., single nucleotide polymorphisms (SNP) and
copy number variations (CNV) in genes coding for PGN sensing molecules and/or
transporters) and external factors such as antibiotic exposure, maternal stress and mode of
delivery. Optimal low PGN levels are needed for the typical brain development. However,
too low or high PGN levels gives rise to atypical brain development.

782

783 Box 1. Factors influencing the development of the infant microbiota

During early postnatal life, the development of the infant gut microbiota follows successive waves of microbial exposures and colonization that is influenced by age-associated events such as dietary transitions (e.g., cessation of breastfeeding and the introduction of solid foods into the diet), leading to a more complex and diverse adult-like ecosystem around the first 2-3 years of age (see Ref. [109]). However, the exact age at which the toddler gut microbiota comes to resemble the adult pattern may vary depending upon the prenatal and neonatal history.

791 Several factors play an important role in shaping the development of the infant microbiota and potential functional outcomes including the mode of delivery (cesarean delivery vs. 792 793 vaginal delivery), breastfeeding practices (breast milk vs. formula feeding) and use of antibiotic (see Refs. [8, 9]). In addition, other factors such as length of gestation (i.e. full-794 term vs. pre-term birth), nutritional status (under- and overnutrition), hospitalization and 795 796 genetics can have a profound impact on neonatal microbial colonization trajectories. The fact that the assembly and maturation of the infant gut microbiota co-occurs in parallel with 797 798 key neurodevelopmental process (e.g., myelination, synaptogenesis, synaptic refinement 799 and acquisition of brain functions) has led to the realization that the early postnatal period 800 represent not only a critical time-window in brain and microbial development, but also a key determinant period of health in later-life [8, 9]. 801

802 Clinician's Corner

Traditionally, the translocation of bacterial products such as peptidoglycans (PGN) to the brain has mainly been considered in the context of infection and inflammation. However, the recent realization of the size and complexity of the human microbiome and its wide ranging impact on host physiology and development has triggered a reevaluation of the possible role of bacterial-derived products and metabolites from the non-pathogenic microbiota on host tissues, including brain development and behavior.

809

PGN from commensal microbiota are ubiquitously present in circulation and can cross the blood brain barrier. PGN-sensing molecules are highly expressed in the normal developing brain and their expression is highly sensitive to manipulations of the gut microbiota, including perinatal antibiotic exposure. Work from transgenic animal models implicate PGNsensing molecules in the control of social behavior and anxiety.

815

PGN sensing molecules are expressed in the human placenta and represent an important mediator for microbiota-host communication at the maternal-fetal interface. Studies in rodents suggest that circulating PGN fragments from maternal gut microbiota can influence the fetal brain, and subsequent cognitive development.

820

From a clinical point of view, detection of PGN levels during the perinatal period could represent a new strategy to screen and identify infants and children at risk of neurodevelopmental and psychiatric disorders such as autism spectrum disorder.

824

At the genetic level, there is a need to explore potential associations between genetic polymorphisms in PGN-sensing molecules (e.g., peptidoglycan recognition proteins and Nodlike receptors) and neurodevelopmental disorders.

828

829











Brain development

